Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu Province, 211198, PR China.
Department of Pharmacology, Nanjing Medical University, Nanjing, 211166, PR China.
Eur J Pharmacol. 2020 Jun 5;876:173049. doi: 10.1016/j.ejphar.2020.173049. Epub 2020 Mar 3.
In the beginning stage of heart disease, the blockage of blood flow frequently occurs due to the persistent damage and even death of myocardium. Cicatricial tissue developed after the death of myocardium can affect heart function, which ultimately leads to heart failure. In recent years, several studies carried out about the use of stem cells such as embryonic, pluripotent, cardiac and bone marrow-derived stem cells as well as myoblasts to repair injured myocardium. Current studies focus more on finding appropriate measures to enhance cell homing and survival in order to increase paracrine function. Until now, there is no universal delivery route for mesenchymal stem cells (MSCs) for different diseases. In this review, we summarize the advantages and challenges of the systemic and local pathways of MSC delivery. In addition, we also describe some advanced measures of cell delivery to improve the efficiency of transplantation. The combination of cells and therapeutic substances could be the most reliable method, which allows donor cells to deliver sufficient amounts of paracrine factors and provide long-lasting effects. The cardiac support devices or tissue engineering techniques have the potential to facilitate the controlled release of stem cells on local tissue for a sustained period. A novel promising epicardial drug delivery system is highlighted here, which not only provides MSCs with a favorable environment to promote retention but also increases the contact area and a number of cells recruited in the heart muscle.
在心脏病的早期阶段,由于心肌的持续损伤甚至死亡,经常会发生血流阻塞。心肌死亡后形成的瘢痕组织会影响心脏功能,最终导致心力衰竭。近年来,有几项关于使用胚胎干细胞、多能干细胞、心脏干细胞和骨髓来源的干细胞以及成肌细胞来修复受损心肌的研究。目前的研究更侧重于寻找适当的措施来增强细胞归巢和存活能力,以增加旁分泌功能。到目前为止,对于不同的疾病,还没有一种通用的间充质干细胞(MSCs)的输送途径。在这篇综述中,我们总结了 MSC 全身和局部输送途径的优缺点。此外,我们还描述了一些先进的细胞输送措施,以提高移植的效率。细胞与治疗物质的结合可能是最可靠的方法,它允许供体细胞提供足够数量的旁分泌因子,并产生持久的效果。心脏支持设备或组织工程技术有可能促进局部组织中干细胞的持续释放。这里突出了一种新的有前途的心外膜药物输送系统,它不仅为 MSCs 提供了一个有利的环境来促进保留,还增加了与心肌的接触面积和募集的细胞数量。